- Home
- VTVT vs LGVN Comparison
VTVT vs LGVN Comparison
Compare VTVT & LGVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VTVT | LGVN |
|---|---|---|
| Founded | 2015 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 127.0M | 12.7M |
| IPO Year | 2015 | 2021 |
Fundamental Metrics
Financial Performance| Metric | VTVT | LGVN |
|---|---|---|
| Price | $39.64 | $0.57 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | ★ $43.50 | $6.50 |
| AVG Volume (30 Days) | 13.8K | ★ 371.8K |
| Earning Date | 11-06-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $17,000.00 | ★ $1,437,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $13.20 | $0.49 |
| 52 Week High | $41.49 | $2.24 |
Technical Indicators
Market Signals| Indicator | VTVT | LGVN |
|---|---|---|
| Relative Strength Index (RSI) | 69.99 | 45.64 |
| Support Level | $33.62 | $0.49 |
| Resistance Level | $41.49 | $0.55 |
| Average True Range (ATR) | 2.26 | 0.03 |
| MACD | 0.22 | 0.00 |
| Stochastic Oscillator | 70.06 | 53.97 |
Price Performance
Historical ComparisonAbout VTVT vTv Therapeutics Inc.
vTv Therapeutics Inc is a late-stage biopharmaceutical company focused on developing oral, small molecule drug candidates intended to help treat people living with diabetes and other chronic diseases. Its clinical pipeline is led by cadisegliatin, currently in a Phase 3 trial, a potential novel first-in-class oral liver-selective glucokinase activator being investigated for the treatment of type 1 diabetes. The group and its development partners are investigating multiple molecules across different indications for chronic diseases. Its product pipeline are HPP737, Azeliragon, TTP-RA, TTP273, HPP971 / HPP3033, and HPP593.
About LGVN Longeveron Inc.
Longeveron Inc is a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs for specific aging-related and life-threatening conditions. Its investigational product is Lomecel-B an stem cell formulation sourced from the bone marrow of young, healthy adult donors and has potential mechanisms of action that can promote tissue repair and healing. The company currently has three pipeline indications: Hypoplastic Left Heart Syndrome (HLHS), Alzheimer's disease (AD) and Aging-related Frailty.